Predict your next investment

HEALTHCARE | Biotechnology
cytomx.com

See what CB Insights has to offer

Founded Year

2008

Stage

IPO | IPO

Total Raised

$133.61M

Date of IPO

10/8/2015

Market Cap

0.46B

Stock Price

6.75

Revenue

$0000 

About CytomX Therapeutics

CytomX Therapeutics (NASDAQ: CTMX) is a biotechnology company developing Probody therapeutics for the treatment of cancer. Probodies are masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, unlocking new therapeutic targets. The Company is focusing this platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of unmet medical need in oncology.

CytomX Therapeutics Headquarter Location

151 Oyster Point Blvd Suite 400

South San Francisco, California, 94080,

United States

650-515-3185

Latest CytomX Therapeutics News

CytomX Therapeutics To Present At Upcoming November Investor Conferences

Nov 11, 2021

Author: SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in virtual fireside chats at the following investor conferences in November. 12 th Annual Jefferies Global Healthcare ConferenceDate: Thursday, November 18, 2021 33 rd Annual Piper Sandler Virtual Healthcare ConferenceDate: Tuesday, November 30, 2021 The Jefferies fireside chat will be made available at 3:00 a.m. ET (8:00 a.m. GMT) on Thursday, November 18, 2021 on the Events and Presentations page of CytomX's website at www.cytomx.com . The Piper Sandler fireside chat will be made available at 10:00 a.m. ET on Monday, November 22, 2021. Archived replays of both fireside chats will be available on the CytomX website for 30 days following the event. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences. About CytomX Therapeutics, Inc.CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX's goal is to transcend the limits of current cancer treatments and successfully leverage therapeutic targets that were once thought to be inaccessible. CytomX's robust and differentiated pipeline includes the wholly-owned praluzatamab ravtansine (CX-2009), an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD166, and CX-2029, an investigational conditionally activated ADC directed toward CD71 co-developed with AbbVie. These two programs are currently being evaluated in Phase 2 studies, targeting a variety of late-stage, difficult-to-treat cancer types, including breast cancer for praluzatamab ravtansine, and squamous non-small cell lung cancer, and head and neck squamous cell carcinoma for CX-2029. CytomX's clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab (CX-072). In addition, CytomX has a diverse preclinical portfolio and strategic collaborations with other leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter. Probody is a U.S. registered trademark of CytomX Therapeutics, Inc. Investor Contact:Chau Cheng, PhD MBAVP, Investor Relations & Corp. Communications ccheng@cytomx.com Direct: (650) 273-4999 Media Contact:Bret CoonsDirector, Corporate Communications bcoons@cytomx.com Direct: (650) 528 2929 By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CytomX Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CytomX Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CytomX Therapeutics Patents

CytomX Therapeutics has filed 89 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Monoclonal antibodies
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/12/2019

11/23/2021

Tyrosine kinase receptors, Clusters of differentiation, Proteins, Experimental cancer drugs, Receptor tyrosine kinase inhibitors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/12/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/23/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Tyrosine kinase receptors, Clusters of differentiation, Proteins, Experimental cancer drugs, Receptor tyrosine kinase inhibitors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CytomX Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

CytomX Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.